Anton P Porsteinsson
Overview
Explore the profile of Anton P Porsteinsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
2858
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sankhe K, Tumati S, Perin J, Rivet L, Vieira D, Rosenberg P, et al.
Int Psychogeriatr
. 2025 Mar;
37(2):100012.
PMID: 40086910
Background: Previous trials have shown improvements in both apathy and cognition with methylphenidate (MPH). Objectives: To assess whether changes in apathy correlated with changes in cognition in the Apathy in...
2.
Butler P, Yang J, Brown R, Hobbs M, Becker A, Penalver-Andres J, et al.
Nat Med
. 2025 Mar;
PMID: 40038507
Consumer-grade mobile devices are used by billions worldwide. Their ubiquity provides opportunities to robustly capture everyday cognition. 'Intuition' was a remote observational study that enrolled 23,004 US adults, collecting 24 ...
3.
Wang L, Hu W, Dong F, Sheng C, Wu J, Han Y, et al.
Geroscience
. 2025 Jan;
PMID: 39888585
Brain network dynamics have been extensively explored in patients with subjective cognitive decline (SCD). However, these studies are susceptible to individual differences, scanning parameters, and other confounding factors. Therefore, how...
4.
Tumati S, Herrmann N, Perin J, Rosenberg P, Lerner A, Mintzer J, et al.
Int Psychogeriatr
. 2024 Sep;
36(12):1232-1244.
PMID: 39297292
Objectives: Among participants with Alzheimer's disease (AD) we estimated the minimal clinically important difference (MCID) in apathy symptom severity on three scales. Design: Retrospective anchor- and distribution-based analyses of change...
5.
Abushakra S, Porsteinsson A, Sabbagh M, Watson D, Power A, Liang E, et al.
Alzheimers Dement (N Y)
. 2024 Aug;
10(3):e12498.
PMID: 39144121
Introduction: The approved amyloid antibodies for early Alzheimer's disease (AD) carry a boxed warning about the risk of amyloid-related imaging abnormalities (ARIAs) that are highest in apolipoprotein E () ε4/ε4...
6.
Lee D, Clark E, Antonsdottir I, Porsteinsson A
J Am Med Dir Assoc
. 2024 Jul;
25(10):105173.
PMID: 39053890
Alzheimer's disease (AD) is a prevalent neurodegenerative disease characterized by progressive cognitive and functional decline. Nearly all patients with AD develop neuropsychiatric symptoms (NPSs). Agitation is one of the most...
7.
Zeng L, Perin J, Gross A, Shade D, Lanctot K, Lerner A, et al.
Int J Geriatr Psychiatry
. 2024 Jun;
39(6):e6108.
PMID: 38858522
Objectives: To examine clinically important adverse events (AEs) associated with methylphenidate (MPH) treatment of apathy in Alzheimer's Disease (AD) versus placebo, including weight loss, vital signs, falls, and insomnia. Methods:...
8.
Zivko C, Sagar R, Xydia A, Lopez-Montes A, Mintzer J, Rosenberg P, et al.
Mol Psychiatry
. 2024 Jun;
29(11):3644-3652.
PMID: 38840027
Alzheimer's disease (AD) is the most common cause of dementia, and the gradual deterioration of brain function eventually leads to death. Almost all AD patients suffer from neuropsychiatric symptoms (NPS),...
9.
Lee D, Antonsdottir I, Clark E, Porsteinsson A
Expert Opin Pharmacother
. 2024 May;
25(7):791-799.
PMID: 38814590
Introduction: Alzheimer's disease (AD) is a neurodegenerative condition characterized by progressive cognitive deterioration, functional impairments, and neuropsychiatric symptoms. Valiltramiprosate is a tramiprosate prodrug being investigated as a novel treatment for...
10.
Clark E, Perin J, Herrmann N, Brawman-Mintzer O, Lanctot K, Lerner A, et al.
Alzheimers Dement (N Y)
. 2023 Aug;
9(3):e12403.
PMID: 37538343
Introduction: Methylphenidate has been shown to improve apathy in patients with Alzheimer's disease (AD). The authors evaluated the impact of methylphenidate on neuropsychiatric symptoms (NPS) of AD, excluding apathy, using...